BNF for Children May 2024 Update

This update contains 8 significant changes, 3 dose changes, 3 new monographs, 1 new preparation and 2 deleted monographs.

Significant Changes:

• Budesonide: update to dosing for modified-release capsules.
• Codeine phosphate linctus (codeine oral solutions): reclassification to prescription-only medicine [MHRA/CHM advice].
• Hydrocortisone: updated indication oral and perioral lesions to aphthous ulcers.
• Hyoscine butylbromide: update to important safety information.
• Malaria, prophylaxis: updated guidance.
• Pneumococcal vaccine: updated guidance for immunisation.
• Pseudoephedrine hydrochloride: very rare risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) [MHRA/CHM advice].
• Vaccination, general principles: updated guidance for immunisation of individuals with asplenia, splenic dysfunction, or complement disorders.

Dose Changes:

• Acetylcysteine [update to dosing for paracetamol overdosage].
• Paracetamol [update to upper weight range for intravenous paracetamol].
• Pneumococcal polysaccharide conjugate vaccine (adsorbed) [update to dosing].

New Monographs:

• Enspryng® [satralizumab].
• Evkeeza® [evinacumab].
• Eylea® [aflibercept].

New Preparations: Otinova® [aluminium acetate].

Deleted Monographs: Chloroquine with proguanil; Proguanil hydrochloride.